The intricate workings of the human brain rest fundamentally upon one critical process: energy metabolism. For decades, scientists have understood that the brain, despite comprising only about 2% of the body’s weight, consumes roughly 20% of the body’s total energy resources. This disproportionate demand underscores how deeply brain function is intertwined with bioenergetics. Recent advancements in neuroscience and metabolic biology have shed light on the intimate relationship between energy production, neuronal activity, and overall cognitive performance. Furthermore, emerging evidence reveals that disruptions in brain energy metabolism are not mere epiphenomena but core contributors to psychiatric disorders. Harnessing this knowledge opens promising avenues for therapeutic developments targeting these metabolic abnormalities.
Neural tissue is exceptionally energy-hungry. The brain’s primary energy currency, adenosine triphosphate (ATP), is produced predominantly through mitochondrial oxidative phosphorylation and glycolysis. Neurons, glial cells, and their supporting vasculature form a sophisticated metabolic network that ensures an uninterrupted flow of glucose and oxygen, facilitating ATP synthesis. Alterations in any segment of this supply chain—be it glucose uptake, glycolytic processing, or mitochondrial function—can exert profound effects on neural signaling and plasticity. Thus, understanding the biochemical pathways of cerebral energy metabolism offers a lens through which to interpret brain health and disease.
In neuropsychiatric disorders such as depression, schizophrenia, bipolar disorder, and autism spectrum disorders, a recurring theme emerges: bioenergetic dysregulation. Research over the past several decades has revealed mitochondrial dysfunction, impaired glucose metabolism, and altered lactate dynamics in afflicted individuals. These anomalies manifest in diminished ATP production, increased oxidative stress, and compromised cellular homeostasis. Brain imaging studies using positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) have supported these biochemical findings, demonstrating region-specific metabolic deficits correlated with clinical symptoms.
Mitochondria, colloquially dubbed the “powerhouses” of the cell, have garnered heightened attention in psychiatry. These organelles are central hubs for energy conversion and reactive oxygen species management. Dysfunctional mitochondria not only falter in ATP generation but also contribute to excessive oxidative damage, triggering apoptosis or cell death. The neurobiological sequelae include synaptic weakening, impaired neurotransmitter release, and altered neural circuitry — all hallmarks observed in psychiatric conditions. Intriguingly, genetic studies have pointed to the involvement of nuclear and mitochondrial DNA variants influencing mitochondrial efficacy, suggesting a heritable component underpinning bioenergetic vulnerability.
On a systemic scale, the bidirectional communication between brain metabolism and peripheral energy states is increasingly recognized. The concept of the “brain-body metabolic axis” posits that disruptions in systemic energy balance—such as insulin resistance, obesity, or metabolic syndrome—can exacerbate or even precipitate neuropsychiatric symptoms. Peripheral metabolic disorders often mirror or potentiate central bioenergetic impairments, creating a vicious cycle that complicates treatment outcomes. This interconnectedness hints that psychiatric disorders might benefit from interventions traditionally reserved for metabolic diseases.
Therapeutic strategies targeting bioenergetic abnormalities are burgeoning. Pharmacological agents aimed at enhancing mitochondrial function, reducing oxidative stress, or modulating glucose metabolism have entered clinical trials with varying degrees of success. For example, compounds like coenzyme Q10, creatine, and nicotinamide adenine dinucleotide (NAD+) precursors have shown potential in restoring mitochondrial efficiency. Additionally, metabolic modulators such as ketone bodies and insulin sensitizers offer alternative fuel sources or improve glucose utilization respectively, yielding symptomatic improvements in some patients.
Lifestyle interventions also represent a pivotal front in remediating bioenergetic deficiencies. Nutritional approaches that optimize glucose availability or promote ketogenesis have demonstrated cognitive and mood benefits. Exercise, known to enhance mitochondrial biogenesis and efficiency, is regularly advocated as an adjunctive treatment. Moreover, novel neuromodulation techniques, including transcranial magnetic stimulation (TMS) and photobiomodulation, are being explored for their capacity to influence cerebral metabolism and ameliorate psychiatric symptoms indirectly.
The challenges that remain are formidable. The heterogeneity of psychiatric disorders complicates the identification of universal bioenergetic biomarkers. Moreover, temporal dynamics—understanding whether energetic deficits are causes or consequences of psychiatric pathology—require longitudinal and mechanistic studies. Advanced imaging technologies combined with molecular profiling promise to unravel these complexities. Precision medicine approaches integrating metabolic signatures could potentially stratify patients for targeted metabolic therapies.
Given the expanding corpus of evidence, future research agendas must emphasize multidimensional integration. Bridging neuroscience, mitochondrial biology, endocrinology, and psychiatry will be paramount. Deep phenotyping of patients coupled with metabolic profiling may facilitate early diagnosis or prognostic evaluation. Additionally, interdisciplinary collaborations can accelerate the development of novel agents that penetrate the blood-brain barrier and selectively enhance cerebral energy production without systemic side effects.
On a molecular level, advancements in single-cell metabolomics and proteomics provide tools to dissect cell-type-specific bioenergetic pathways. This granularity can elucidate how distinct neuronal populations or glial subtypes contribute to overall brain energy homeostasis and vulnerability. Unraveling the interplay between neuron and astrocyte metabolism, particularly the astrocyte-neuron lactate shuttle hypothesis, may reveal therapeutic targets that optimize substrate delivery and utilization.
Furthermore, the epigenetic modulation of metabolic genes introduces another layer of complexity and opportunity. Environmental stress, inflammation, and early life adversity can induce lasting changes in metabolic gene expression, influencing susceptibility to psychiatric conditions. Therapies aimed at reversing these epigenetic marks or enhancing metabolic resilience could reshape the future of mental health treatment.
In light of these insights, it is evident that the brain’s energy metabolism is not a peripheral player but a central determinant of psychiatric health. Disentangling the metabolic underpinnings of mental illness offers hope for innovative treatments that move beyond symptom management toward root cause remediation. The integration of metabolic diagnostics and therapeutics into clinical psychiatry holds promise not only for improved outcomes but also for a paradigm shift in understanding mental disorders.
To capitalize on the burgeoning knowledge, researchers and clinicians must pursue comprehensive, mechanistic studies coupled with translational efforts. The prospect of tailoring interventions based on individual metabolic profiles is an exciting horizon. As neuropsychiatry continues to embrace metabolic perspectives, the potential exists to unveil novel biomarkers, optimize pharmacological regimens, and ultimately enhance patient quality of life.
The marriage of brain bioenergetics with psychiatric research symbolizes a pivotal chapter in neuroscience. Advancements here may answer longstanding questions about the biological substrates of mental illness and drive the development of metabolically informed therapies. As we stand on the cusp of this new frontier, the urgency to fund and focus research efforts on brain-body energy interactions has never been greater.
This evolving understanding underscores a simple yet profound truth: to heal the mind, we must first understand and support the engine that powers it. With continued exploration into brain and body energy metabolism, the prospect for revolutionizing treatment paradigms for psychiatric disorders is within reach, illuminating a path toward more effective and enduring mental health interventions.
Subject of Research: Brain and body energy metabolism’s role in the pathophysiology and treatment potential for psychiatric disorders.
Article Title: Brain and body energy metabolism and potential for treatment of psychiatric disorders
Article References:
Andreazza, A.C., Barros, L.F., Behnke, A. et al. Brain and body energy metabolism and potential for treatment of psychiatric disorders. Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00422-6
Image Credits: AI Generated
